RNU6-916P

Across TCGA pan-cancer cohorts, RNU6-916P RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated RNU6-916P data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RNU6-916P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-916P expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

OV, COAD, and MESO are the cancer types where RNU6-916P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	II,III,IV	0.385	0.697	<.001	126	view →
COAD	OS	Tertile	All	0.163	0.870	<.001	108	view →
MESO	DFS	Tertile	III,IV	0.086	0.387	<.001	72	view →
READ	DFS	Tertile	All	0.255	0.844	.004	45	view →
ACC	OS	Tertile	All	0.133	0.631	.017	45	view →
LUSC	OS	Tertile	All	0.305	0.728	.015	18	view →
LAML	DFS	Tertile	All	0.028	0.572	<.001	18	view →
PRAD	OS	Tertile	All	0.619	0.889	<.001	18	view →
THCA	OS	Tertile	III,IV	0.738	0.985	.002	15	view →
ESCA	DFS	Tertile	III,IV	1.000	0.279	.036	12	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

RNU6-916P–OV (OS)

Open the OV breakdown →